| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 7.6 | 7.2 |
| Gross profit | 1.5 | 1.6 |
| Profit before tax | -0.7 | -0.3 |
| Net income | -0.6 | -0.0 |
| EPS (diluted, $ a share) | $-0.09 | $-0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +6.3% |
|---|---|
| Gross margin | 19.9% |
| Operating margin | -10.0% |
10-Q filed with the SEC, NYSE: AMS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
American Shared Hospital Services: key numbers
- Share price
- $1.03Close, Nov 17
- Market cap
- $6.88M
- Shares outstanding
- 6.67MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from American Shared Hospital Services
All →American Shared Hospital Services Earnings Call: Key Takeaways
AMS reports 13.7% nine-month revenue growth driven by direct patient services, but faces significant net losses and high legal costs due to debt restructuring.
- Call
- Nov 12, 2026, 12:00 PM ET
American Shared Hospital Services Financial Results
American Shared Hospital Services reported Q3 2026 revenue of $7.6 million, a 6% increase year-over-year, driven by a 14% rise in Direct Patient Services revenue. The company generated $5.8 million in operating cash flow during the first nine months of 2026 and increased its cash position to approximately $9.5 million.
“During the third quarter, we continued to make progress in growing our Direct Patient Services business, with revenue in this segment increasing 14% year over year. For the first nine months of 2026, total revenue increased 14%, driven by continued growth in our Rhode Island radiation therapy operations and higher procedure volumes at our international Gamma Knife facilities.”
Craig Tagawa, Interim Chief Executive Officer
“We continue to focus on positioning the Company for long-term success by building on our established presence in radiation oncology and pursuing opportunities to expand the reach and capabilities of our technology and services.”
Ray Stachowiak, Executive Chairman